论文部分内容阅读
目的:探讨替米沙坦联合贝那普利对永久性心脏起搏器植入患者血浆脑利钠肽(BNP)水平的影响.方法:96例植入永久性心脏起搏器的患者按随机数字表法分为A、B、C组,每组32例.在常规治疗的基础上,术后即给予A组患者替米沙坦80 mg/d、B组患者贝那普利10 mg/d、C组患者替米沙坦40 mg/d+贝那普利10 mg/d.均每日1次,连服6个月.比较3组患者的左室射血分数(LEVF)、心脏指数(CI)、肾素活性(Ren)以及血浆BNP、血管紧张素Ⅱ(AngⅡ)、醛固酮(Ald)的水平.结果:给药6个月后,3组患者的BNP水平均较给药前升高,差异有统计学意义(P<0.05),但C组较A、B组低,差异有统计学意义(P0.05),但A、B组均下降,差异有统计学意义(P<0.05),且C组的LVEF、CI水平均较A、B组高,差异有统计学意义(P<0.05);3组患者的Ren、AngⅡ、Ald水平均较给药前有所下降,差异有统计学意义(P<0.05),且C组较A、B组更低,差异有统计学意义(P<0.05).结论:替米沙坦联合贝那普利对永久性心脏起搏器植入患者的心室重塑和心脏功能有改善作用,能降低血浆BNP水平.“,”OBJECTIVE:To exlpore the effect of telmisartan combine with benazepril on plasma brain natriuretic peptide (BNP) of patients underwent permanent cardiac pacemaker implantation. METHODS:96 patients underwent permanent cardiac pacemaker implantation were randomly divided into group A,B and C with 32 cases in each group. Based on routine treatment, group A was given telmisartan 80 mg/d immediately after operation,qd,group B given benazepril 10 mg/d,qd,group C given telmisartan 40 mg/d+ benazepril 10 mg/d,qd. All of them was given medicine for 6 months. LEVF,CI,Ren,BNP,AngⅡ and Ald were compared among 3 groups. RESULTS:After 6 months,BNP levels of 3 groups were higher than before,with statistical significance (P0.05);those of group A and B were decreased,with statistical significance(P<0.05);those of group C were higher than those of group A and B, with statistical significance(P<0.05). The levels of Ren,AngⅡ and Ald in 3 groups were decreased after treatment,with statisti-cal significance (P<0.05);those of group C were lower than those of group A and B,with statistical significance (P<0.05). CONCLUSIONS:Telmisartan combined with benazepril can improve ventricular remodeling and heart function,and reduce plasma BNP levels in patients underwent permanent cardiac pacemaker implantation.